View in EDS

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

Saved in:
Bibliographic Details
Title: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Authors: Epstein-Peterson ZD; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Drill E; Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center., Aypar U; Department of Pathology, Memorial Sloan Kettering Cancer Center., Batlevi CL; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Caron P; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Dogan A; Department of Pathology, Memorial Sloan Kettering Cancer Center., Drullinsky P; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Gerecitano J; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Hamlin PA; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Ho C; Department of Pathology, Memorial Sloan Kettering Cancer Center., Jacob A; Adaptive Biotechnologies, Seattle, WA., Joseph A; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Laraque L; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Matasar MJ; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Moskowitz AJ; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Moskowitz CH; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Mullins C; Adaptive Biotechnologies, Seattle, WA., Owens C; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Salles G; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Schöder H; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY., Straus DJ; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Younes A; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Zelenetz AD; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center., Kumar A; Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center. kumara@mskcc.org.
Source: Haematologica [Haematologica] 2024 Apr 01; Vol. 109 (4), pp. 1149-1162. Date of Electronic Publication: 2024 Apr 01.
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1592-8721
DOI:10.3324/haematol.2023.282898